In the NEC G3 case, the tumor mutational burden (TMB) was intermediate with 4.32 non-coding mutations per megabase; besides a TP53 mutation, several cyclin pathway alterations (CDKN2A mutation, CCND1 mutation, CDK6 amplification) were detected. The gene discussed is CDKN2A; the disease is neuroendocrine carcinoma.